We are live on ! Find out more

OKYO Pharma

OKYO

Market cap $75M

1.43 USD

+0.03

2.14%

At close Updated Nov 6, 4:00 PM EST

1 day

2.14%

5 days

-2.05%

1 month

-2.05%

3 months

-7.14%

6 months

-14.88%

Year to date

-35.87%

1 year

-45.63%

5 years

-60.5%

10 years

-60.5%

About: OKYO Pharma Ltd is a clinical-stage ophthalmology company focused on developing differentiated therapies for corneal and anterior segment diseases. It is advancing a pipeline designed to improve outcomes for patients suffering from debilitating ocular diseases that impact vision and ocular comfort. The company's main program, urcosimod, is being developed as a potential treatment for neuropathic corneal pain. Additionally, its development pipeline includes an exploratory candidate, OK-201, a non-opioid analgesic drug candidate, as a potential drug to treat acute and chronic ocular pain. The company has only one operating segment: the research and development of biotechnological and pharmaceutical products.

Employees: 5

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 16.7%

Neutral 83.3%

Negative 0%

OKYO Pharma to Present at the Stifel 2026 Healthcare Conference

LONDON and NEW YORK, Nov. 05, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that it will participate at the Stifel 2026 Healthcare Conference November 10–12, 2026. Robert J. Dempsey, Chief Executive Officer, is scheduled to present at 9:20 a.m.

OKYO Pharma to Present at the Stifel 2026 Healthcare Conference

Proactive Investors

OKYO Pharma enrolls first patients in Phase 3 trial of neuropathic corneal pain drug

OKYO Pharma Ltd (NASDAQ:OKYO) enrolled the first patients in its Phase 3 trial of urcosimod for neuropathic corneal pain, a chronic and often severe eye condition with no FDA-approved treatment, the company said on Tuesday. The registrational NEPTUNE study has activated its first US site, with additional sites opening throughout medical centers across the country, OKYO said.

OKYO Pharma enrolls first patients in Phase 3 trial of neuropathic corneal pain drug

OKYO Pharma Announces First Patients Enrolled in Phase 3 Pivotal Trial of Urcosimod for Neuropathic Corneal Pain

LONDON and NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced first patients enrolled in Phase 3 NEPTUNE trial of urcosimod for neuropathic corneal pain (NCP).

OKYO Pharma Announces First Patients Enrolled in Phase 3 Pivotal Trial of Urcosimod for Neuropathic Corneal Pain

OKYO Pharma Presents and Participates at Upcoming Ophthalmic Scientific Conferences

LONDON and NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that it will present and participate at upcoming ophthalmic conferences.

OKYO Pharma Presents and Participates at Upcoming Ophthalmic Scientific Conferences

OKYO Pharma to Present at Ophthalmology Futures European Forum and iNovation Day at ESCRS 2026

LONDON and NEW YORK, Sept. 09, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that it will present at Ophthalmology Futures Forum and in the 5th Annual ESCRS iNovation Day.

OKYO Pharma to Present at Ophthalmology Futures European Forum and iNovation Day at ESCRS 2026

OKYO Pharma to Participate in a Fireside Chat at the Cantor Global Healthcare Conference

LONDON and NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced participation at the Cantor Global Healthcare Conference being held September 9-11, 2026.

OKYO Pharma to Participate in a Fireside Chat at the Cantor Global Healthcare Conference

OKYO Pharma Announces Purchase of Shares by Chief Scientific Officer

LONDON and NEW YORK, July 28, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that Raj Patil, PhD, Chief Scientific Officer of OKYO Pharma has increased his holdings with the purchase of 3,363 of the Company's ordinary shares on NASDAQ at $1.49 per share, bringing his total holding to 20,030 ordinary shares. About OKYO Pharma OKYO Pharma Limited (Nasdaq: OKYO) is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, with ordinary shares listed for trading on the Nasdaq Capital Market.

OKYO Pharma Announces Purchase of Shares by Chief Scientific Officer

OKYO Pharma to Participate in the BTIG Biotechnology Conference 2026

LONDON and NEW YORK, July 27, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced its participation in the BTIG Biotechnology Conference 2026 taking place virtually on July 28-29, 2026.

OKYO Pharma to Participate in the BTIG Biotechnology Conference 2026

OKYO Pharma Announces Purchase of Shares by Director

LONDON and NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that OKYO Pharma's Non-Executive Director, John Brancaccio has purchased 5,000 of the Company's ordinary shares on NASDAQ at $1.48 per share, bringing his total holding to 35,201 shares.

OKYO Pharma Announces Purchase of Shares by Director

OKYO Pharma Announces Purchase of Shares by Chief Executive Officer

LONDON and NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that OKYO Pharma's Chief Executive Officer, Robert J. Dempsey, has purchased 15,000 of the Company's ordinary shares on NASDAQ at $1.54 per share.

OKYO Pharma Announces Purchase of Shares by Chief Executive Officer

See News Rankings

Price charts implemented using Lightweight Charts™